These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20088796)

  • 1. Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
    Crispi S; Cardillo I; Spugnini EP; Citro G; Menegozzo S; Baldi A
    Curr Cancer Drug Targets; 2010 Feb; 10(1):19-26. PubMed ID: 20088796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
    Dragon J; Thompson J; MacPherson M; Shukla A
    J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease.
    Galetta D; Catino A; Misino A; Logroscino A; Fico M
    Tumori; 2016; 102(2):127-30. PubMed ID: 26108245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma.
    Paajanen J; Bueno R; De Rienzo A
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
    Giusti L; Da Valle Y; Bonotti A; Donadio E; Ciregia F; Ventroni T; Foddis R; Giannaccini G; Guglielmi G; Cristaudo A; Lucacchini A
    Proteomics Clin Appl; 2014 Apr; 8(3-4):258-68. PubMed ID: 24415579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
    Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
    Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
    J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
    Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
    Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
    Nuvoli B; Galati R
    Mol Cancer Ther; 2013 Jun; 12(6):844-52. PubMed ID: 23729401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
    Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
    Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinogenicity of amosite asbestos.
    Selikoff IJ; Hammond EC; Churg J
    Arch Environ Health; 1972 Sep; 25(3):183-6. PubMed ID: 5048236
    [No Abstract]   [Full Text] [Related]  

  • 12. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.
    Gee GV; Koestler DC; Christensen BC; Sugarbaker DJ; Ugolini D; Ivaldi GP; Resnick MB; Houseman EA; Kelsey KT; Marsit CJ
    Int J Cancer; 2010 Dec; 127(12):2859-69. PubMed ID: 21351265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma.
    Puntoni R; Filiberti R; Cerrano PG; Neri M; Andreatta R; Bonassi S
    Mutat Res; 2003 Nov; 544(2-3):385-96. PubMed ID: 14644341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.
    Del Gobbo A; Fiori S; Gaudioso G; Bonaparte E; Tabano S; Palleschi A; Bosari S; Ferrero S
    Int J Clin Exp Pathol; 2014; 7(5):2484-9. PubMed ID: 24966960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.
    Wang Y; Jiang Z; Yan J; Ying S
    Dis Markers; 2019; 2019():4183157. PubMed ID: 30891101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological and environmental aspects of asbestos-associated diseases.
    Jones JS
    Med Sci Law; 1974 Jul; 14(3):152-8. PubMed ID: 4444447
    [No Abstract]   [Full Text] [Related]  

  • 17. Malignant mesothelioma presenting in the pleura and peritoneum.
    Mischler NE; Chuprevich T; Johnson RO; Tormey DC
    J Surg Oncol; 1979; 11(3):185-91. PubMed ID: 459514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.
    Hama R; Watanabe Y; Shinada K; Yamada Y; Ogata Y; Yoshida Y; Tamura T; Hiraishi T; Oikawa R; Sakurai J; Maehata T; Koizumi H; Itoh F
    Tumour Biol; 2012 Dec; 33(6):2031-40. PubMed ID: 22836805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
    Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
    Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.
    Petri GL; Cascioferro S; Parrino B; Peters GJ; Diana P; Giovannetti E
    Pharmacogenomics; 2018 Jul; 19(10):811-814. PubMed ID: 29916298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.